A Phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy

Radiotherapy and Oncology

Volumn 40, Issue 1, 1996, Pages 55-58

  Shibamoto, Yuta ^a   Takahashi, Masaji ^a   Abe, Mitsuyuki ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

Author keywords

Clinical study; Fluorinated 2 nitroimidazole; Hypoxic cell sensitizer; KU 2285

Indexed keywords

2,2 DIFLUORO N (2 HYDROXYETHYL) 3 (2 NITRO 1 IMIDAZOLYL)PROPIONAMIDE; NITROIMIDAZOLE DERIVATIVE; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN LYMPHOMA; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LUNG CANCER; LYMPHOMA; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOSENSITIZATION;

EID: 0030200968     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/0167-8140(96)01740-9     Document Type: Article

References (16)

1. [1] Brown, D.M., Gonzalez-Mendez, R. and Brown, J.M. Factors influencing intracellular uptake and radiosensitization by 2-nitroimidazoles in vitro. Radiat. Res. 93: 492-505, 1983.
2. [2] Chassagne, D., Charreau, I., Sancho-Garnier, H., Eschwege, F. and Malaise, E.P. First-analysis on tumor regression for the European randomized trial of etanidazole combined with radiotherapy in head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 22: 581-584, 1992.
3. [3] Coleman, C.N., Wasserman, T.H., Urtasun, R.C., Halsey, J., Noll, L., Hancock, S. and Phillips, T. L. Final report of the Phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole) Radiation Therapy Oncology Group 83-03. Int. J. Radiat. Oncol. Biol. Phys. 18: 389-393, 1990.
4. [4] Iwai, H., Matsuno, E., Sasai, K., Shibamoto, Y. and Abe, M. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Int. J. Radiat. Oncol. Biol. Phys. 29: 591-594, 1994.
5. [5] Lee, D.-J., Pajak, T.F., Marcial, V.A., Fu, K., Rotman, M., Cooper, J.S., Ortiz, H.G., Beitler, J.J., Abrams, R.A., Curran, W.J., Coleman, C.N. and Wasserman, T.H. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int. J. Radiat. Oncol. Biol. Phys. 32: 567-576, 1995.
6. [6] Overgaard, J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol. Res. 6: 509-518, 1994.
7. [7] Overgaard, J., Sand Hansen, H., Lindelov, B., Overgaard, M., Jorgensen, K., Rasmusson, B. and Berthelsen, A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. Suppl. 20: 143-149, 1991.
8. [8] Oya, N., Shibamoto, Y., Sasai, K., Sugiyama, T. and Abe, M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int. J. Radiat. Oncol. Biol. Phys. 27: 1113-1119, 1993.
9. [9] Oya, N., Shibamoto, Y., Shibata, T., Sasai, K., Sugiyama, T. and Abe, M. Combined cytokinesis-block micronucleus and chromosomal aberration assay for the evaluation of radiosensitizers at low radiation doses. Int. J. Radiat. Oncol. Biol. Phys. 30: 1153-1159, 1994.
10. [10] Riese, N.E., Loefller, J.S., Wen, P., Alexander, E. III, Black, P.M. and Coleman, C.N. A phase 1 study of etanidazole and radiotherapy in malignant glioma. Int. J. Radiat. Oncol. Biol. Phys. 29: 617-620, 1994.
11. [11] Sasai, K., Fushiki, M., Yukawa, Y., Suyama, S., Iwai, H., Shibamoto, Y., Nishimoto, S., Takahashi, M. and Abe, M. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int. J. Radiat. Oncol. Biol. Phys. 21: 1231-1234, 1991.
12. [12] Sasai, K., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Kitakabu, Y., Shibamoto, Y., Zhou, L., Wang, J., Takahashi, M., Kagiya, T. and Abe, M. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int. J. Radiat. Oncol. Biol. Phys. 20: 1249-1254, 1991.
13. [13] Shibamoto, Y., Nishimoto, S., Mi, F., Sasai, K., Kagiya, T. and Abe, M. Evaluation of various types of new hypoxic cell sensitizers using the EMT6 single cell-spheroid-solid tumour system. Int. J. Radiat. Biol. 52: 347-357, 1987.
14. [14] Shibamoto, Y., Nishimoto, S., Shimokawa, K., Hisanaga, Y., Zhou, L., Wang, J., Sasai, K., Takahashi, M., Abe, M. and Kagiya, T. Characteristics of fluorinated nitroazoles as hypoxic cell radiosensitizers. Int. J. Radiat. Oncol. Biol. Phys. 16: 1045-1048, 1989.
15. [15] Shibamoto, Y., Streffer, C., Sasai, K., Oya, N. and Abe, M. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int. J. Radiat. Biol. 61: 473-478, 1992.
16. [16] Shibata, T., Shibamoto, Y., Oya, N., Sasai, K., Murata, R., Ishigaki, T. and Abe, M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int. J. Radiat. Oncol. Biol. Phys. 29: 587-590, 1994.